Oral Bisphosphonate Osteoporosis Drugs Could Nearly Double Your Risk of Cancer
September 24, 2010
Spread the Word to
Friends And Family
By Sharing this Article.
Oral bisphosphonate osteoporosis drugs, which include such Actonel, Boniva, and Fosamax, could be associated with an approximately twofold increased risk of esophageal cancer.
A new study showed that long-term users of the drugs had nearly double the risk for the rare but deadly cancer.
Concerns about a link between bisphosphonates and esophageal cancer first reached the public a year and a half ago, when an FDA report cited 23 cases of the cancer in Fosamax users in the U.S., and another 31 cases in Europe and Japan.
"The ... analysis included close to 3,000 patients with cancer of the esophagus, 2,000 patients with stomach cancer, and 10,600 patients with colorectal cancer diagnosed between 1995 and 2005. Each cancer case was compared with five people without cancer matched for age and sex."
Stay Up-To-Date on the Latest Health News
If you haven't already, here's your chance to subscribe to the world's most popular newsletter! My FREE newsletter is instrumental in changing the lives of many people across the world. If you want to take control of your health then you won't want to miss out on this opportunity.
When you subscribe I guarantee:
- You'll be the first to hear about fast-breaking health news and hard-to-find tips for improving your emotional, physical, and spiritual well-being
- You'll save money because I'm committed to helping you stay healthy, so you won't need expensive prescription drugs or doctor's visits so often
- You'll get straight talk from me in plain English that shatters all the myths and misconceptions about health, aging, and fitness
Don't be left in the dark on breaking health news! Sign up for my daily newsletter today!